A certain category of diabetes drugs, including Januvia of Merck &Co Inc has been found to incite joint pain as per the FDA findings. The agency has identified several cases where patients have experienced server joint pain when they have been prescribed DPP-4 inhibitors. The cases have arisen over a period of seven years, between 2006 and 2013. The most frequent occurrences are linked to Januvia, which is called sitagliptin generically. Other drugs that have shown similar side effects include Nesina by Takeda Pharmaceuticals as well as Tradjenta by Boehringer Ingelheim. The reasons behind Januvia showing up the maximum number of cases is because it was first to be marketed and is also prescribed by most doctors. About eighty percent of DPP-4 drugs that are prescribed include Januvia in US.

Merck officials have announced that all safety regulations and risks that are found are considered seriously by the company and they were working with FDA to ensure that these side effects are removed from the sitagliptin class of drugs. Other companies like Boehringer Ingelheim stated that, they had conducted clinical trials with Tradjenta in order to see the implications on connective tissue and musculoskeletal disorders where the imbalance was not found.

Joint Pain Risks Are Present With DPP-4 Diabetes Drugs As Per FDA Regulations

The symptoms that were found in patients continued for a month for which FDA suspected the DPP-4 inhibitors to be the cause of the problem. The drugs are commonly prescribed to patients who have type 2 diabetes, which helps to lower the blood sugar level in the body. The FDA proposed that the patients need not stop taking the drug, but in case of a persistent and sever form of joint pain experienced, one needs to contact their doctor.

FDA has asked the drug manufacturers to issue a warning as well as a precaution statement on the drugs, stating the risk of joint pain that can occur. All drugs in this class can exhibit the same symptoms. Patients as well as caregivers are asked to report in any pain that is experienced by taking in DPP-4 level of inhibitors. These drugs are usually prescribed in order to stabilize the blood sugar levels, which go high after a meal is consumed. Merck is closely working with FDA to issue safety guidelines and to come up with an alternative form of the drugs in order to help reduce this side effect as seen in patients. Those who are prescribed this class of drugs for their type 2 diabetes condition need to notify their doctors if they come across joint pain.